Blog - Page 4145 of 5482

MondayNov 03, 2008 6:32 am

Fronteer Development Group, Inc. (AMEX: FRG)

Fronteer Development Group, Inc. (AMEX: FRG), a gold-focused exploration and development company, has dedicated its efforts to discovering and advancing large deposits with substantial production potential. The company currently has a portfolio of advanced-stage gold projects in Nevada, a 40% interest in three gold and copper-gold projects in Turkey, and a 42.2% interest in Aurora Energy Resources (AXU-TSX), a leading Canadian uranium company. For further information, visit the Company's web site at www.fronteergroup.com.

MondayNov 03, 2008 6:32 am

Warren Resources, Inc. (NASDAQ: WRES)

Warren Resources, Inc. (NASDAQ: WRES), an independent energy company, is focused on the exploration and development of domestic onshore natural gas and oil reserves. The company is one of the leading developers of coalbed methane natural gas in the Rocky Mountain region. As of the end of 2007, Warren owned natural gas and oil interests in approximately 230,738 gross (129,555 net) acres. The company has plans to develop its California properties through directional and horizontal drilling. For further information, visit the Company's web site at www.warrenresources.com.

MondayNov 03, 2008 6:31 am

First Nickel Inc. (TSX: FNI CN)

First Nickel Inc. (TSX: FNI CN), a Canadian mining and exploration company, has its focus primarily on the Sudbury Basin in northern Ontario, the location of four of its exploration properties and the Lockerby Mine. Indicated resources at its Lockerby Mine increased ten-fold since it was acquired by First Nickel in 2005. In addition to the properties above, the company also has two exploration properties in the Timmins region of northern Ontario. For further information, visit the Company's web site at www.firstnickel.com.

MondayNov 03, 2008 6:31 am

WaferGen Biosystems, Inc. (OTC BB: WGBS)

WaferGen Biosystems, Inc. (OTC BB: WGBS) is focused on developing, manufacturing and commercializing next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries. The company is developing what could become the platform of choice for genetic analysis as well as cell monitoring enabling genomics and cell biology from research to clinic. WaferGen’s innovative systems are the first of their kind, providing researchers with critical performance advantages that are not available with existing technologies. For further information, visit the Company's web site at www.wafergen.com.

MondayNov 03, 2008 6:31 am

First Majestic Silver Corp. (TSX: FR CN)

First Majestic Silver Corp. (TSX: FR CN) is focused on building a senior Silver producing mining company by executing an aggressive development and acquisition plan within the borders of Mexico. Currently, the company owns and operates three producing silver mines in Mexico: the La Parrilla Silver Mine, the San Martin Silver Mine and the La Encantada Silver Mine. It is anticipated that production from these three mines will reach 4.5 million ounces of silver in 2008 with further increases in 2009 and beyond. For further information, visit the Company's web site at www.firstmajestic.com.

MondayNov 03, 2008 6:31 am

Vyteris, Inc. (OTC BB: VYTR)

Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company's web site at www.vyteris.com.

MondayNov 03, 2008 6:30 am

VIVUS, Inc. (NASDAQ: VVUS)

VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company, is focused on developing and commercializing next-generation therapeutic products designed to target obesity and sexual health. The potential market for obesity ranges from $5 billion to $10 billion annually according to speculating analysts, while the potential market for an effective diabetes therapy that causes weight loss is in excess of $2 billion. The indications targeted by VIVUS' sexual health products each represent a potential market of more than $1 billion per annum. For further information, visit the Company's web site at www.vivus.com.

MondayNov 03, 2008 6:30 am

VirtualScopics, Inc. (NASDAQ: VSCP)

VirtualScopics, Inc. (NASDAQ: VSCP) provides superior precision and reproducibility through their computer-assisted analysis techniques. The company’s technologies enable faster and more reliable detection of disease progression or therapeutic benefit, accelerating the clinical trial process, and providing a foundation for future diagnostic applications. VirtualScopics’ originates from research initially undertaken at the University of Rochester Medical Center and School of Engineering. For further information, visit the Company's web site at www.virtualscopics.com.

MondayNov 03, 2008 6:29 am

ViroPharma Incorporated (NASDAQ: VPHM)

ViroPharma Incorporated (NASDAQ: VPHM), a multinational biotechnology company, is focused on developing and commercializing innovative products that target unmet medical needs. The company is currently dedicating their efforts to developing these products for physician specialists that support patients with serious diseases caused by CMV, C. difficile, and hereditary angioedema. Maribavir, VioPharma’s lead clinical compound, is an orally-administered antiviral Phase 3 drug designed to prevent cytomegalovirus (CMV) disease in transplant patients. For further information, visit the Company's web site at www.viropharma.com.

MondayNov 03, 2008 6:29 am

VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP)

VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP) , a New Jersey-based biotechnology company, is focused on becoming a leader in the successful development of novel drug therapies designed to target both the molecular basis of cancer and side effects of treatment. The company’s oncology portfolio currently includes: Xyfid™, for the treatment of dry skin conditions and to manage the burning and itching associated with various dermatoses; VQD-002, a targeted inhibitor of Akt activation; and Lenocta™, an inhibitor of certain protein tyrosine phosphatases. For further information, visit the Company's web site at www.vioquestpharm.com.

Site Search

Company Search

Fronteer Development Group, Inc. (AMEX: FRG)

Warren Resources, Inc. (NASDAQ: WRES)

First Nickel Inc. (TSX: FNI CN)

WaferGen Biosystems, Inc. (OTC BB: WGBS)

First Majestic Silver Corp. (TSX: FR CN)

Vyteris, Inc. (OTC BB: VYTR)

VIVUS, Inc. (NASDAQ: VVUS)

VirtualScopics, Inc. (NASDAQ: VSCP)

ViroPharma Incorporated (NASDAQ: VPHM)

VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP)

Market Basics

Newsletter Publishers

Public Companies